PRECISIS

PRECISIS operates in the medical-device and neuroscience segments, with a focused position in neuromodulation for drug-resistant focal epilepsy. Its main differentiator is the EASEE system’s minimally invasive configuration: electrodes are placed under the scalp and above the skull, allowing targeted stimulation without direct contact with brain tissue. The company’s positioning is supported by European availability following CE certification, UK clinical use in 2025, FDA authorization for a U.S. trial, and the EASEE4YOU collaboration with Great Ormond Street Hospital. PRECISIS also combines device development with clinical research and patient-facing guidance through EPI-GUIDE. Its competitive constraints include the need to generate further clinical evidence, expand adoption among epilepsy specialists, and navigate regulatory and reimbursement requirements across markets. The company remains private and appears to be a specialized rather than broad-based digital-health platform.

PRECISIS shows a progression from long-term product development to clinical expansion. The company was founded in 2004, while the documented financing history includes a $20 million venture round announced on Oct 14, 2021 and a €2.50 million European Innovation Council grant recorded on Oct 5, 2022, converted in the company’s financial summary to $2.47 million. EASEE received CE certification by 2022, enabling European availability, and the company subsequently expanded clinical activity into the United Kingdom with a first reported implantation on Apr 28, 2025. The December 2025 launch of the EASEE4YOU study at Great Ormond Street Hospital extended the product’s clinical scope to adolescents. FDA authorization for a pivotal trial, reported on Nov 6, 2025, creates a potential U.S. development inflection point, but does not itself establish approval or commercialization. Growth indicators generated in 2026 describe funding, headcount, and operations as improving. At the same time, the absence of open roles and limited public workforce detail make the pace and scale of expansion difficult to quantify.